CRISPR Therapeutics CRSP EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's EPS (basic)?
- CRISPR Therapeutics (CRSP) reported EPS (basic) of -$1.28 in Q1 2026.
- How has CRISPR Therapeutics's EPS (basic) changed year-over-year?
- CRISPR Therapeutics's EPS (basic) increased by 19.0% year-over-year, from -$1.58 to -$1.28.
- What is the long-term trend for CRISPR Therapeutics's EPS (basic)?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's EPS (basic) has grown at a -11.8% compound annual growth rate (CAGR), from -$8.36 to -$6.50.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.